<DOC>
	<DOCNO>NCT00812669</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine cyclophosphamide , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving fludarabine together cyclophosphamide rituximab may kill cancer cell . PURPOSE : This phase II trial study give fludarabine together cyclophosphamide rituximab see well work treat patient chronic lymphocytic leukemia .</brief_summary>
	<brief_title>CLL-Irl Study . ICORG 07-01 , V7</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate efficacy , term complete remission rate , fludarabine phosphate , cyclophosphamide , rituximab patient chronic lymphocytic leukemia . Secondary - Determine time treatment failure ( TTF ) patient . - Determine overall survival patient 10 year . - Assess predictive value immunophenotype , hypermutation analysis , FISH determine TTF OS patient . - Determine safety profile regimen . OUTLINE : This multicenter study . Patients receive fludarabine IV 30 minute orally cyclophosphamide IV orally day 1-3 pegfilgrastim subcutaneously day 4 . Starting course 2 , patient receive rituximab IV day 1 . Treatment repeat every 28 day 6* course absence disease progression unacceptable toxicity . NOTE : *Patients achieve negative minimal residual disease receive 4 course treatment . Blood sample collect periodically biomarker analysis . Samples analyze protein expression ( i.e. , CD38 , CD20 , ZAP70 ) flow cytometry ; quantitative immunoglobulin , β2-microglobulin , T-cell subsets electrophoresis ; IgVH mutation status ; cytogenetics ( i.e. , +12 , del 13q , del 11q , del 17p ) FISH . After completion study therapy , patient follow every 6 month 5 year annually 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic lymphocytic leukemia Stage IIV disease ( Binet stage progressive A , B , C ) CD5 CD23 positive Untreated OR relapsed/resistant disease combination chemotherapy rituximab No 17p deletion PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy &gt; 1 year Creatinine clearance ≥ 50 mL/min HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent malignancy except noninvasive cervical cancer localize nonmelanomatous skin cancer No history anaphylaxis mousederived humanized monoclonal antibody No severe concurrent ( e.g. , cardiac pulmonary ) diseases mental disorder could interfere ability participate study PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>